Liquidity and going-concern pressure
The company has a small cash balance and has relied on equity proceeds, product sales, and asset sales to fund operations.
- Scope
- Corporate funding and operating continuity
- Materiality
- high
Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. is a U.S.-based commercial-stage company that has shifted from agricultural trait development toward consumer products and selective monetization of intellectual property. Its current operating business centers on Zola coconut water products, while legacy wheat trait assets and the GoodWheat brand have been sold or exited. The company also has a history of licensing and royalty activity tied to wheat-based technologies, but it no longer expects future license or royalty income from its wheat intellectual property. Recent disclosures show a business in transition, with product sales, asset sales, and patent monetization playing a larger role than ongoing agricultural R&D commercialization.
−50,8 %
36,2 %
−48,1 %
−3,7 %
3.09
2.50
| % | |
|---|---|
| Beverage products | 70% Coconut water and related hydration products sold under the Zola brand. |
| Nutritional oils | 10% GLA oil products sold through product channels, with sales ending at the close of 2024. |
| Intellectual property monetization | 15% Sales of patents, pending applications, and related intangible assets from legacy agricultural technologies. |
| Legacy agricultural technology | 5% Residual wheat trait-related commercialization and licensing activity, now largely exited. |
Arcadia’s current customers are primarily third-party distributors and retailers that buy Zola coconut water and...
- Beverage distributors and retailersprimary
Buy Zola coconut water for resale in grocery, convenience, and other beverage channels because the product is a branded hydration item with seasonal consumer demand.
- GLA product channel buyerssecondary
Purchase GLA oil products through product sales channels, although this segment has diminished as GLA oil sales ceased at the end of 2024.
- Intellectual property acquirers and licenseessecondary
Buy or license patent portfolios and related rights, such as the March 2025 sale of reduced gluten and oxidative stability patents and the 2024 RS durum wheat trait sale.
- Legacy agricultural commercialization partnersemerging
Previously bought seed, grain, food ingredients, and trait rights tied to wheat technologies, but this segment is now largely exited.
The company is headquartered in the United States and its disclosures point to a primarily U.S...
- •Headquartered in the United States
- •Current operations are centered on U.S. consumer-product distribution
- •Patent and asset sales have been executed with U.S.-based counterparties
- •No country-level revenue disclosure was provided in the excerpts
- •Geographic exposure is mainly to U.S. retail demand and logistics
Arcadia’s strategy has shifted from agricultural trait development toward monetizing remaining assets while supporting...
01
Support and simplify the Zola beverage businessshort-term
Zola is the remaining operating product line and the main source of recurring product revenue.
02
Monetize legacy intellectual propertyshort-term
Asset sales provide non-recurring cash and reduce the burden of maintaining non-core technologies.
03
Exit or wind down non-core agricultural activitiesmedium-term
The company has already exited GoodWheat and no longer expects wheat royalty income, indicating a strategic pivot away from the old model.
Arcadia faces execution and liquidity risk because its business has been reduced to a small set of product lines and...
Residual intellectual property monetization risk
The company has sold key patent portfolios and no longer expects future wheat royalty income, limiting future IP cash flows.
- Scope
- Legacy technology assets
- Materiality
- high
Seasonality in coconut water demand
Sales volumes are highest in the second and third fiscal quarters, making results uneven across periods.
- Scope
- Zola beverage revenue
- Materiality
- medium
Dependence on third-party distributors and retailers
Revenue is recognized on delivery and fluctuates with shipment timing, which can delay or accelerate reported sales.
- Scope
- Product revenue recognition
- Materiality
- medium
Revenue recognition on product sales
Quarterly revenue volatility and net sales presentation
Inventory net realizable value
Cost of revenues and margin volatility
Gain on sale of intangible assets
Non-operating income and comparability
Seasonality of beverage sales
Revenue, inventory, and cash flow timing
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
PRECISION BIOSCIENCES INC
DTIL · Biological Products, (No Diagnostic Substances)
Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform.
ASSEMBLY BIOSCIENCES, INC.
ASMB · Pharmaceutical Preparations
Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances)
Vita Coco Company, Inc.
COCO · Beverages
: 11/08/2026